Form 4: Natera Co-Founder Jonathan Sheena Reports Stock Sales and RSU Acquisition

Jonathan Sheena, co-founder of Natera, Inc., reports the sale of common stock and acquisition of Restricted Stock Units (RSUs) through recent transactions.

Summary

• On February 29, 2024, Jonathan Sheena, co-founder of Natera, Inc., sold shares of common stock at various prices ranging from approximately $85.17 to $90.1750 per share.
• The sales were executed under two pre-arranged Rule 10b5-1 trading plans adopted on December 13, 2022, and March 13, 2023.
• A total of 12,000 shares were sold across multiple transactions.
• On March 1, 2024, Sheena acquired 1,028 Restricted Stock Units (RSUs), which were fully vested upon issuance, each representing a contingent right to receive one share of Natera's common stock.
• Following these transactions, Sheena directly owns 464,613 shares of Natera common stock and indirectly owns 29,310 shares through Caraluna 1 Trust and Caraluna 2 Trust for the benefit of minor children.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions are part of pre-planned trading arrangements. The RSU acquisition is a slightly positive sign, but the stock sales offset this.

Positives

• The acquisition of 1,028 Restricted Stock Units (RSUs) indicates continued alignment with the company's long-term success.

Negatives

• The sale of shares by a co-founder, even under a pre-arranged trading plan, could be perceived negatively by some investors.

Risks

• Continued stock sales by insiders could create downward pressure on the stock price.
• Investor sentiment may be affected by insider trading activity, regardless of the pre-planned nature of the transactions.

Future Outlook

The document does not contain specific forward-looking statements, but it indicates continued stock transactions under existing Rule 10b5-1 trading plans.

Industry Context

Insider trading activity is closely monitored in the biotech industry, and Form 4 filings provide transparency into these transactions. Investors often analyze these filings to gauge management's sentiment and confidence in the company's future prospects.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among corporate insiders to diversify their holdings while avoiding accusations of trading on non-public information.
• The frequency and volume of insider transactions are often compared to those of peers in the diagnostics and genetic testing industry, such as Exact Sciences (EXAS) or Invitae (NVTA), to assess relative insider sentiment.

Stakeholder Impact

• Shareholders may react to the stock sales, potentially influencing the stock price.
• Employees may perceive the insider transactions as a reflection of management's confidence in the company.

Key Dates